Cognito Therapeutics is wrapping up the largest clinical trial ever conducted on a non-drug device for Alzheimer’s disease. The HOPE study, a randomized, double-blind, sham-controlled trial of the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by ...

Cognito's frequency of lights and sounds are designed to sync up with the brain’s gamma waves, a pattern associated with memory, attention and overall cognitive function. (monsitj / iStock / Getty ...

Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...

Cognito Therapeutics has delivered clinical data from its digital treatment for patients with Alzheimer’s disease—which relies on light and sound to stimulate specific electrical frequencies in the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late-stage developer of disease-modifying therapies to treat neurodegenerative disorders, announced today continued active treatment in the ...

Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. This voice experience is generated by AI. Learn more. This ...